These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16206354)

  • 21. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Reginster JY
    Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
    Riis BJ; Ise J; von Stein T; Bagger Y; Christiansen C
    J Bone Miner Res; 2001 Oct; 16(10):1871-8. PubMed ID: 11585352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
    Chesnut CH
    Drugs; 2006; 66(10):1351-9. PubMed ID: 16903769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-monthly ibandronate.
    Dando TM; Noble S
    Treat Endocrinol; 2005; 4(6):381-7; discussion 389-90. PubMed ID: 16318406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.
    Dempster DW; Bolognese MA
    J Clin Densitom; 2006; 9(1):58-65. PubMed ID: 16731432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
    Amling M; Kurth A
    Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quarterly intravenous ibandronate for postmenopausal osteoporosis.
    Emkey RD
    Womens Health (Lond); 2008 May; 4(3):219-28. PubMed ID: 19072470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
    Recker RR; Weinstein RS; Chesnut CH; Schimmer RC; Mahoney P; Hughes C; Bonvoisin B; Meunier PJ
    Osteoporos Int; 2004 Mar; 15(3):231-7. PubMed ID: 14727011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
    Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.
    Bala Y; Kohles J; Recker RR; Boivin G
    Calcif Tissue Int; 2013 Jan; 92(1):6-14. PubMed ID: 23090678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
    Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
    Miller PD; Recker RR; Reginster JY; Riis BJ; Czerwinski E; Masanauskaite D; Kenwright A; Lorenc R; Stakkestad JA; Lakatos P
    Osteoporos Int; 2012 Jun; 23(6):1747-56. PubMed ID: 21953471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.